ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "COVID-19"

  • Abstract Number: 0108 • ACR Convergence 2021

    Efficacy of SARS-CoV-2 Vaccine in Patients with Rheumatic Diseases: A Systematic Review and Meta-Analysis

    Akhil Sood1, Vijaya Murthy1 and Emilio Gonzalez2, 1University of Texas Medical Branch, League City, TX, 2University of Texas Medical Branch (utmb Health), Galveston, TX

    Background/Purpose: The mRNA-based SARS-CoV-2 vaccine has shown efficacy in large vaccine trials. However, patients on immunosuppressive therapies including those with rheumatic disease (RD) were excluded.…
  • Abstract Number: 0437 • ACR Convergence 2021

    Factors Associated with Reduced Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) Treated with Rituximab

    Victoria Furer1, Tali Eviatar2, Devy Zisman3, Hagit Peleg4, Daphna Paran5, David Levartovsky1, Ilana Kaufman6, Michael Zisapel1, Ofir Elalouf7, Roni Meidan1, Adi Broyde8, Ari Polachek9, Jonathan Wollman7, Katya Meridor10, Hila Nochomovitz1, Adi Silberman1, Dana Rosenberg1, Joy Feld11, Amir Haddad12, Tal Gazitt13, Muna Elias3, Nizar Hijaze14, Fadi Kharouf4, Gabi Shefer1, Orly Sharon1, Sara Pel1, Sharon Nevo1 and Ori Elkayam15, 1Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 2Tel Aviv Sourasky Medical Center, Givataim, Israel, 3Carmel Medical Center, Haifa, Israel, 4Hadassah Medical Center, Jerusalem, Israel, 5Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel, 6Tel Aviv Sourasky Medical Center, Petach Tiqwa, Israel, 7Tel Aviv Medical Center, Herzliya, Israel, 8Tel Aviv Sourasky Medical Center, KIBBUTZ GIVAT HAIM I, Israel, 9Sourasky Medical Center, Petah-Tikva, Israel, 10Tel Aviv Sourasky Medical Center, Kfar Saba, Israel, 11Carmel and Zvulun Medical Centre, Haifa, Israel, 12Carmel Medical Centre, Haifa, Israel, 13Carmel Hospital, Haifa, Israel, 14Carmel medical centre, Tamra, Israel, 15Tel Aviv Medical Center, Tel Aviv, Israel

    Background/Purpose: Rituximab (RTX) has been associated with impaired humoral response to vaccination. This study aim was to identify the predictors for a lack of humoral…
  • Abstract Number: 0866 • ACR Convergence 2021

    Characteristics Associated with Poor COVID-19 Outcomes in People with Systemic Lupus Erythematosus (SLE): Data from the COVID-19 Global Rheumatology Alliance (GRA)

    Manuel Ugarte-Gil1, Graciela Alarcn2, Andrea Seet3, Zara Izadi3, Ali Duarte-Garcia4, Cristina Reategui-Sokolova5, Ann Clarke6, Leanna Wise7, Guillermo Pons-Estel8, Maria José Santos9, Sasha Bernatsky10, Sandra Lúcia Ribeiro11, Samar Al Emadi12, Jeffrey Sparks13, Tiffany Hsu14, Kristin D'Silva15, Naomi Patel15, Emily Gilbert16, Maria Valenzuela-Almada17, Andreas Jnsen18, Gianpiero Landolfi19, Micaela Fredi20, Tiphaine Goulenok21, Mathilde Devaux22, Xavier Mariette23, Viviane Queyrel24, Vasco C Romão25, Graça Sequeira26, Rebecca Hasseli27, Bimba Franziska Hoyer28, Reinhard Voll29, Christof Specker30, Roberto Baez31, Vanessa Castro Coello32, Edgard Neto33, Gilda Ferreira34, Odirlei Andre Monticielo35, Emily Sirotich36, Jean Liew37, Jonathan Hausmann38, Paul Sufka39, Rebecca Grainger40, Suleman Bhana41, Wendy Costello42, Zachary Wallace43, Lindsay Jacobsohn44, Anja Strangfeld45, Elsa Frazão Mateus46, Kimme Hyrich47, Laure Gossec48, Loreto Carmona1, Saskia Lawson-Tovey47, Lianne Kearsley-Fleet49, Martin Schaefer50, Pedro Machado51, Philip Robinson52, Milena Gianfrancesco3 and Jinoos Yazdany3, 1Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, 2University of Alabama at Birmingham, Birmingham, AL, 3University of California San Francisco, San Francisco, CA, 4Mayo Clinic, Rochester, MN, 5Hospital Guillermo Almenara Irigoyen, Lima, Peru, 6University of Calgary, Calgary, AB, Canada, 7LAC+USC/Keck Medicine of USC, Pasadena, CA, 8Centro Regional de Enfermedades Autoinmunes y Reumaticas (CREAR), Rosario, Argentina, 9Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, 10McGill University, Montréal, QC, Canada, 11Universidade Federal do Amazonas, Amazonas, Brazil, 12Hamad medical corporation, Doha, Qatar, 13Brigham and Women's Hospital, Boston, MA, 14Brigham and Women's Hospital, Jamaica Plain, MA, 15Massachusetts General Hospital, Boston, MA, 16Mayo Clinic, Jacksonville, FL, 17Division of Rheumatology, Mayo Clinic, Rochester, MN, 18Lund University, Lund, Sweden, 19Epidemiology Research Unit, Italian Society for Rheumatology, Milan, Italy, 20Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, 21Internal Medicine Department, Bichat Claude Bernard Hospital, Paris, France, 22Service de Médecine Interne, CHI Poissy Saint Germain, Poissy, France, 23Université Paris- Saclay, Rheumatology, Paris, France, 24University Hospital of Nice, Nice, France, 25Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre and European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET); Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, 26Centro Hospitalar Universitário do Algarve, Unidade de Faro, Faro, Portugal, 27Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus Liebig University Giessen, Bad Nauheim, Germany., Bad Nauheim, Germany, 28Universittsklinikum Schleswig-Holstein, Kiel, Germany, 29Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, 30Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany, 31Hospital Francisco Lopez Lima, General Roca, Rio Negro, Argentina, 32Sanatorio Güemes, Buenos Aires, Argentina, 33UNIFESP, São Paulo, Brazil, 34Federal University of Minas Gerais, Belo Horizonte, Brazil, 35Serviço de Reumatologia do Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 36McMaster University, Hamilton, ON, Canada, 37Boston University, Boston, MA, 38Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, 39HealthPartners, Eagan, MN, 40University of Otago, Wellington, New Zealand, 41Crystal Run Health, Montvale, NJ, 42Irish Children's Arthritis Network, Bansha, Ireland, 43Massachusetts General Hospital, Newton, MA, 44University of California San Francisco, Antioch, CA, 45Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 46Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, 47University of Manchester, Manchester, United Kingdom, 48Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, 49Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, 50German Rheumatism Research Center, Berlin, Germany, 51Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 52Faculty of Medicine, The University of Queensland, Herston, Australia

    Background/Purpose: Preliminary data in people with SLE suggested that disease activity as well as SLE treatment at time of COVID-19 acquisition impact COVID-19 outcomes over…
  • Abstract Number: 1066 • ACR Convergence 2021

    Evaluation of a Non-Face to Face Multidisciplinary Health Care Model in a Population with Rheumatoid ArthritisVulnerable to Covid-19 in a Health Emergency Situation

    Pedro Santos-Moreno1, Rosangela Casanova2, Gabriel-Santiago Rodríguez-Vargas2, Laura Villareal1, Jaime-Andrés Rubio2, Josefina Chávez-Chávez2, Diana Patricia Rivera-Triana2, Ruth Alexandra Castiblanco-Montañez2, Sandra Milena Hernández-Zambrano2 and Adriana Rojas-Villarraga2, 1BIOMAB IPS, Bogotá, Colombia, 2Fundación Universitaria de Ciencias de la Salud-FUCS, Bogotá, Colombia

    Background/Purpose: The COVID-19 pandemic impacted everyday practice pattern of health care in rheumatoid arthritis (RA) patients. The objective was to evaluate the implementation of a…
  • Abstract Number: 1452 • ACR Convergence 2021

    COVID-19 Infection Among Autoimmune/Auto-inflammatory Rheumatic Disease Patients: Data from an Observational Study

    Clio Mavragani1, Athanasios-Dimitrios Bakasis2, Kyriaki Boki3, Athanasios Tzioufas4, Panayiotis Vlachoyiannopoulos1, Ioanna Stergiou5, Fotini Skopouli6 and Haralampos Moutsopoulos7, 1National and Kapodistrian University of Athens, Athens, Greece, 21 Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, 33 Rheumatology Unit, Sismanoglio General Hospital, Athens, Greece, Athens, Greece, 4Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, 5Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, 6Department of Nutrition and Clinical Dietetics, Harokopio University of Athens, Athens, Greece, 7Athens Academy of Athens, Chair Medical Sciences/Immunology, Athens, Greece

    Background/Purpose: The impact of COVID-19 infection in patients with autoimmune/auto-inflammatory rheumatic diseases (AARD) under immunomodulatory treatment is not entirely clear and deeper knowledge is of…
  • Abstract Number: 1544 • ACR Convergence 2021

    Clinical Course and Risk Factors for Severe/Critical COVID-19 in Patients with Rheumatic Diseases – a Multicenter, Nationwide Study

    Sofia Carvalho Barreira1, Ana Rita Cruz-Machado1, Matilde Bandeira1, Catarina Duarte2, Maria Rato3, Bruno Fernandes4, Salomé Garcia3, Filipe Pinheiro3, Miguel Bernardes3, Nathalie Madeira5, Cláudia Miguel5, Rita Torres6, Ana Bento Silva6, Jorge Pestana7, Diogo Almeida8, Carolina Mazeda9, Filipe Cunha Santos10, Patrícia Pinto11, Marlene Sousa12, Hugo Parente13, Graca Sequeira14, Maria José Santos7, João Eurico Fonseca15 and Vasco C Romão15, 1Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Center; Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, 2Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, 3Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Porto, Portugal, 4Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Braga, Portugal, 5Rheumatology Department, Instituto Português de Reumatologia, Lisbon, Portugal, 6Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal, 7Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, 8Rheumatology Department, Hospital de Braga, Braga, 9Rheumatology Department - Centro Hospitalar do Baixo Vouga and Ibimed, Institute for Biomedicine, University of Aveiro, Aveiro, Portugal, 10Rheumatology Department, Local Health Unit of Guarda, Guarda, Portugal, 11Rheumatology Department, Centro Hospitalar de Vila Nova de Gaia/Espinho, Gaia, Portugal, 12Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, 13Rheumatology Department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal., Ponte de Lima, Portugal, 14Rheumatology Department, Centro Hospitalar Universitário do Algarve, Faro, Portugal, 15Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre and European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET); Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

    Background/Purpose: Since the beginning of the COVID-19 pandemic, some studies have addressed risk factors for severe forms of the disease in patients with rheumatic diseases.…
  • Abstract Number: 1562 • ACR Convergence 2021

    B Cell Reconstitution Is Strongly Associated with COVID-19 Vaccine Responsiveness in Rheumatic Disease Patients Treated with Rituximab

    Sarah Jinich, Deanna Jannat-Khah and Robert Spiera, Hospital for Special Surgery, New York, NY

    Background/Purpose: Rituximab (RTX) has previously been shown to impair antibody response to vaccines such as influenza and streptococcus. Recently, diminished COVID-19 vaccine responsiveness in RTX…
  • Abstract Number: 1604 • ACR Convergence 2021

    Perceptions About COVID-19 Vaccination Among Patients with Rheumatic Diseases Enrolled in a National Patient Registry

    Maria I. Danila1, Kelly Gavigan2, Esteban Rivera2, Michael George3, Jeffrey Curtis4, William Nowell2 and Shilpa Venkatachalam2, 1University of Alabama at Birmingham, Birmingham, AL, 2Global Healthy Living Foundation, Upper Nyack, NY, 3University of Pennsylvania, Philadelphia, PA, 4Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: COVID-19 vaccine confidence is key to promoting vaccination efforts to mitigate the spread of COVID-19 among people with rheumatic diseases. The goal of this…
  • Abstract Number: 1640 • ACR Convergence 2021

    Multisystem Inflammatory Syndrome in Children at Two Tertiary Hospitals in Cape Town, South Africa: Clinical Phenotype and Distinguishing Features from Similar Acute Inflammatory Conditions

    Claire Butters1, Deepthi Abraham2, Heidi Facey-Thomas1, Debbie Abrahams1, Ayodele Faleye3, Helena Rabie2, Christiaan Scott4, Liesl Zühlke5 and Kate Webb6, 1Paediatric Rheumatology, University of Cape Town, Cape Town, South Africa, 2Tygerberg Hospital, Stellenbosch University, Cape Town, South Africa, 3Lagos state university teaching hospital Ikeja, Lagos, Nigeria, 4University of Cape Town, Faculty of Health Science, Cape Town, South Africa, 5Paediatric Cardiology, University of Cape Town, Cape Town, South Africa, 6University of Cape Town, Cape Town, South Africa

    Background/Purpose: Distinguishing Multisystem Inflammatory Syndrome in Children (MIS-C) associated with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) from acute, pyrexial childhood illness can be challenging.…
  • Abstract Number: 0092 • ACR Convergence 2021

    Clinical Outcomes of Patients with Systemic Rheumatic Diseases Hospitalized for COVID-19 at a Large Academic Center in New York City

    Caroline Siegel1, Jacky Choi2, Debra D'Angelo2, Paul Christos2, Lindsay Lally1, Parag Goyal2, Lisa Mandl1 and Medha Barbhaiya1, 1Hospital for Special Surgery, New York, NY, 2Weill Cornell Medicine, New York, NY

    Background/Purpose: While patients with systemic rheumatic diseases (SRDs) are in general more vulnerable to infections due to their underlying immune dysregulation and immunomodulatory therapies, data…
  • Abstract Number: 0109 • ACR Convergence 2021

    COVID-19 Infection and Outcomes in Patients with Rheumatic Diseases: A Systematic Review and Meta-Analysis

    Akhil Sood1, Ronak Gandhi2, Vijaya Murthy1, Emilio Gonzalez3 and Mukaila Raji2, 1University of Texas Medical Branch, League City, TX, 2University of Texas Medical Branch, Galveston, TX, 3University of Texas Medical Branch (utmb Health), Galveston, TX

    Background/Purpose: Early studies published at the beginning of COVID-19 pandemic suggested lower risk of COVID-19 and less severe disease course in patients with rheumatic diseases…
  • Abstract Number: 0444 • ACR Convergence 2021

    COVID-19 Vaccination in Autoimmune Disease (CoVAD) Study: Interim Analysis of Safety in Idiopathic Inflammatory Myopathies from a Large Multicentre Global Survey

    Latika Gupta1, James Lilleker2, Vishwesh Agarwal3, Sinan Kardes4, Marcin Milchert5, Tamer Gheita6, Babur Salim7, Tsvetelina Velikova8, Oliver Distler9, Hector Chinoy10, Vikas Aggarwal1 and Rohit Aggarwal11, 1Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, 2Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, The University of Manchester, Centre for Musculoskeletal Research,, Manchester, United Kingdom, 3Mahatma Gandhi Mission Medical College, Navi Mumbai, India, 4Medical Ecology and Hydroclimatology Istanbul Faculty of Medicine, Istanbul, Turkey, 5Katedra Reumatologii i Chorób Wewnętrznych, Klinika Chorób Wewnętrznych Reumatologii Diabetologii Geriatrii i Immunologii Klinicznej PUM, ul. Unii Lubelskiej 1, 71-252 Szczecin,, Szczecin, Poland, 6Cairo University, Egypt, Cairo, Egypt, 7Fauji Foundation Hospital, Rawalpindi, Pakistan, 8University Hospital Lozenetz, Sofia, Bulgaria, 9Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland, 10University of Manchester, Salford, United Kingdom, 11University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Numerous Covid-19 vaccines have demonstrated efficacy and safety against SARS-CoV-2 in general population. Despite favorable adverse effect (ADRs) profile of vaccines, there have been…
  • Abstract Number: 0876 • ACR Convergence 2021

    Antibody Response in Patients with Systemic Lupus Erythematosus After a Two-dose Regimen with SARS-CoV-2 Vaccines (Preliminary Results)

    Emilie Stavnsbjerg Larsen1, Anna Christine Nilsson2, Ulrik Stenz Justesen1, Anne Voss3 and Isik Somuncu Johansen4, 1Odense University Hospital, Odense C, Denmark, 2Odense Universitets Hospital, Odense C, Denmark, 3Department of Rheumatology, Odense University Hospital, Odense C, Denmark, 4Odense University Hospital, Odense, Denmark

    Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) often receive immunosuppressive treatment for many years, resulting in higher risk of infections, including COVID-19, and infections may…
  • Abstract Number: 1067 • ACR Convergence 2021

    Experiences of Self-Care During the COVID-19 Pandemic Among Individuals with Rheumatoid Arthritis: A Qualitative Study

    Jenny Leese1, Catherine L. Backman1, Jasmin Ma1, Cheryl Koehn2, Alison Hoens3, Kelly English3, Eileen Davidson4, Shanon McQuitty3, James Gavin5, Jo Adams5, Stephanie Thierren6 and Linda Li1, 1University of British Columbia, Vancouver, BC, Canada, 2Arthritis Consumer Experts, Vancouver, BC, Canada, 3Arthritis Research Canada Arthritis Patient Advisory Board, Vancouver, BC, Canada, 4Arthritis Research Canada Arthritis Patient Advisory Board, Burnaby, BC, Canada, 5University of Southampton, Southampton, United Kingdom, 6Arthritis Research Canada, Richmond, BC, Canada

    Background/Purpose: The COVID-19 pandemic poses new challenges for individuals with rheumatoid arthritis (RA) to manage their self-care, such as being physically active, maintaining emotional wellbeing,…
  • Abstract Number: 1524 • ACR Convergence 2021

    COVID-19 Vaccination Rates and Adverse Events Among Patients on Immunosuppressive Therapy in the Rheumatology Clinic Caring for an Underserved Population

    Suguni Gallappaththy1, Sarah Ifteqar2 and Amr Edrees3, 1University of Missouri Kansas City, Kansas City, KS, 2UMKC, Kansas City, MO, 3UMKC, Overland Park, KS

    Background/Purpose: Patients with autoimmune inflammatory rheumatic disease (AIRD) are at a higher risk for serious infections due to a combination of disease related immune dysfunction…
  • « Previous Page
  • 1
  • …
  • 22
  • 23
  • 24
  • 25
  • 26
  • …
  • 38
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology